Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.60 |
| ▸ | GSK3B | P49841 | 3/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | HTR7 | P34969 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | HTR5A | P47898 | 1/20 | 0.60 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.60 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.59 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.56 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.56 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | CDK9 | P50750 | 1/20 | 0.56 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30507329 | 1.00 | HSP90AA1 (0.60) | HSP90AA1GSK3BDYRK1AHTR1AHTR7 | |
| SCHEMBL30507427 | 0.86 | DYRK1A (0.60) | HSP90AA1GSK3BDYRK1AHTR1AHTR7 | |
| SCHEMBL28508238 | 0.86 | DYRK1A (0.60) | HSP90AA1GSK3BDYRK1AHTR1AHTR7 | |
| SCHEMBL13977463 | 0.84 | JAK2 (0.53) | HSP90AA1GSK3BDYRK1AHTR1AHTR7 | |
| SCHEMBL28511492 | 0.84 | CDK5 (0.58) | HSP90AA1GSK3BDYRK1AHTR1AHTR7 | |
| SCHEMBL30507237 | 0.84 | CDK5 (0.58) | HSP90AA1GSK3BDYRK1AHTR1AHTR7 | |
| SCHEMBL27346672 | 0.83 | CYP1A2 (0.67) | GSK3BCDK5CDK9ALDH1A1KDM4E | |
| SCHEMBL28501601 | 0.83 | CDK5 (0.59) | HSP90AA1GSK3BDYRK1AHTR1AHTR7 | |
| SCHEMBL30507533 | 0.83 | CDK5 (0.59) | HSP90AA1GSK3BDYRK1AHTR1AHTR7 | |
| SCHEMBL15939816 | 0.81 | CHRNA7 (0.55) | HSP90AA1GSK3BDYRK1AHTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113549018-B | Protein kinase inhibitor and derivative thereof, preparation method, pharmaceutical composition and application | 中国药科大学 | 2024-02-27 | — | — | CN | disclosed |
| CN-112010844-B | Preparation method and application of N- (pyrimidine-2-yl) coumarin-7-amine derivative as protein kinase inhibitor | 中国药科大学 | 2023-07-25 | — | — | CN | disclosed |
| CN-113549018-A | Protein kinase inhibitor and derivative thereof, preparation method, pharmaceutical composition and application | 中国药科大学 | 2021-10-26 | — | — | CN | disclosed |
| CN-112010844-A | Preparation method and application of N- (pyrimidine-2-yl) coumarin-7-amine derivative as protein kinase inhibitor | 中国药科大学 | 2020-12-01 | — | — | CN | disclosed |
| WO-2010138575-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010046780-A2 | ANTI VIRAL COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010046780-A2 | ANTI VIRAL COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2010-04-29 | — | — | WO | disclosed |
| US-20090215777-A1 | Pyrimidine Derivatives As HSP90 Inhibitors | ASTEX THERAPEUTICS LTD. (GB) | 2009-08-27 | — | — | US | disclosed |
| US-20090215777-A1 | Pyrimidine Derivatives As HSP90 Inhibitors | ASTEX THERAPEUTICS LTD. (GB) | 2009-08-27 | — | — | US | disclosed |
| US-20090215777-A1 | Pyrimidine Derivatives As HSP90 Inhibitors | ASTEX THERAPEUTICS LTD. (GB) | 2009-08-27 | — | — | US | disclosed |
| EP-2049497-A2 | PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS | Astex Therapeutics Limited (GB) | 2009-04-22 | — | — | EP | disclosed |
| WO-2006123165-A2 | PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215777-A1 | Pyrimidine Derivatives As HSP90 Inhibitors | HSP90AB1, HSP90AB2P, HSP90B1 | HSP90AA1 4/4885GSK3B 243/4885DYRK1A 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.